Batch of approvals and positive opinions from EU's CHMP

The European medicines Agency's (EMEA) Committee for Medicinal Products for Human Use, (CHMP) adopted positive opinions at its October 19-22 meeting, recommending the granting of a marketing authorization, for the following new medicines:

* Scintimun (besilesomab), from CIS bio international, a radiopharmaceutical intended for use in scintigraphic imaging, in conjunction with other appropriate imaging modalities, for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis. The review of Scintimun began on July 23, 2008, with an active review time of 203 days.